Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Cedilanid D
2. Cedilanid-d
3. Cedilanidd
4. Desacetyl Lanatoside
5. Desacetyldigilanide C
6. Desacetyllanatoside C
7. Deslanatoside C
8. Lanatoside, Desacetyl
1. 17598-65-1
2. Desacetyllanatoside C
3. Deacetyllanatoside C
4. Cedilanid-d
5. Deslanosidum
6. Deslanosido
7. Glucodigoxin
8. Deslanosid
9. Deacetylanatoside C
10. Desacetyl-lanatoside C
11. Desace
12. Lanatoside C, Deacetyl-
13. Ygy317rk75
14. Sediranido
15. Lekozid
16. Chebi:31468
17. Deslanosidum C
18. Dsstox_cid_2897
19. Dsstox_rid_76778
20. Dsstox_gsid_22897
21. (3beta,5beta,12beta)-3-{[beta-d-glucopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide
22. Deslanosidum [inn-latin]
23. Deslanosido [inn-spanish]
24. Deacetyl-lanatoside C
25. Cedilanid-d (tn)
26. Cas-17598-65-1
27. Einecs 241-568-1
28. Brn 0078187
29. Unii-ygy317rk75
30. Cedilanide
31. Deslanoside [usp:inn:ban:jan]
32. Ncgc00159441-02
33. Deslanoside [mi]
34. Deslanoside [inn]
35. Deslanoside [jan]
36. Deslanoside [vandf]
37. Chembl1614
38. Deslanoside [mart.]
39. Deslanoside [usp-rs]
40. Deslanoside [who-dd]
41. 3beta-(o-beta-d-glucopyranosyl-(1-4)-o-beta-d-digitoxosyl-(1-4)-o-beta-d-digitoxosyl-(1-4)-beta-d-digitoxosyloxy-12beta,14-dihydroxy-5beta,14beta-card-20(22)-enolid
42. 4-18-00-02455 (beilstein Handbook Reference)
43. Card-20(22)-enolide, 3-((o-beta-d-glucopyranosyl-(1-4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)-
44. Schembl125311
45. Gtpl6806
46. Deslanoside (jp17/usp/inn)
47. Dtxsid1022897
48. Deslanoside [orange Book]
49. Deslanoside [ep Monograph]
50. Deslanoside [usp Impurity]
51. Hy-a0154
52. Tox21_111671
53. Mfcd00135818
54. Tox21_111671_1
55. Zinc253668332
56. Db01078
57. Ncgc00159441-03
58. 3-[(o-beta-d-glucopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide
59. 3beta-{[beta-d-glucopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl]oxy}-12beta,14-dihydroxy-5beta-card-20(22)-enolide
60. Card-20(22)-enolide, 3-((o-beta-d-glucopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)-
61. Cs-0017480
62. D01240
63. E88575
64. 598d651
65. Q5264583
66. (3beta,5beta,12beta)-3-{[beta-d-glucopyranosyl-(1-->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide
67. 3-[(o-beta-d-glucopyranosyl-(1-->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide
68. Card-20(22)-enolide, 3-((o-.beta.-d-glucopyranosyl-(1->4)-o-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3.beta.,5.beta.,12.beta.)-
| Molecular Weight | 943.1 g/mol |
|---|---|
| Molecular Formula | C47H74O19 |
| XLogP3 | -0.3 |
| Hydrogen Bond Donor Count | 9 |
| Hydrogen Bond Acceptor Count | 19 |
| Rotatable Bond Count | 10 |
| Exact Mass | 942.48243013 g/mol |
| Monoisotopic Mass | 942.48243013 g/mol |
| Topological Polar Surface Area | 282 Ų |
| Heavy Atom Count | 66 |
| Formal Charge | 0 |
| Complexity | 1760 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 26 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment and management of Congestive cardiac insufficiency, arrhythmias and heart failure.
Deslanoside is a cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation.
Cardiotonic Agents
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
C - Cardiovascular system
C01 - Cardiac therapy
C01A - Cardiac glycosides
C01AA - Digitalis glycosides
C01AA07 - Deslanoside
Absorption
Little absorption from the gastrointestinal tract (40%).
36 hours
Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Deslanoside also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.
Market Place
REF. STANDARDS & IMPURITIES
USP
ABOUT THIS PAGE
A Deslanoside manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Deslanoside, including repackagers and relabelers. The FDA regulates Deslanoside manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Deslanoside API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Deslanoside manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Deslanoside supplier is an individual or a company that provides Deslanoside active pharmaceutical ingredient (API) or Deslanoside finished formulations upon request. The Deslanoside suppliers may include Deslanoside API manufacturers, exporters, distributors and traders.
click here to find a list of Deslanoside suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Deslanoside Drug Master File in Japan (Deslanoside JDMF) empowers Deslanoside API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Deslanoside JDMF during the approval evaluation for pharmaceutical products. At the time of Deslanoside JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Deslanoside suppliers with JDMF on PharmaCompass.
Deslanoside Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Deslanoside GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Deslanoside GMP manufacturer or Deslanoside GMP API supplier for your needs.
A Deslanoside CoA (Certificate of Analysis) is a formal document that attests to Deslanoside's compliance with Deslanoside specifications and serves as a tool for batch-level quality control.
Deslanoside CoA mostly includes findings from lab analyses of a specific batch. For each Deslanoside CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Deslanoside may be tested according to a variety of international standards, such as European Pharmacopoeia (Deslanoside EP), Deslanoside JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Deslanoside USP).
LOOKING FOR A SUPPLIER?
